Arcus Biosciences Current Ratio 2017-2022 | RCUS

Arcus Biosciences current ratio from 2017 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Arcus Biosciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $1.23B $0.16B 7.48
2022-03-31 $1.26B $0.16B 7.84
2021-12-31 $1.26B $0.17B 7.60
2021-09-30 $0.55B $0.14B 3.82
2021-06-30 $0.75B $0.13B 5.72
2021-03-31 $0.84B $0.13B 6.38
2020-12-31 $0.74B $0.12B 6.05
2020-09-30 $0.80B $0.16B 4.90
2020-06-30 $0.47B $0.04B 11.78
2020-03-31 $0.17B $0.02B 7.91
2019-12-31 $0.19B $0.02B 8.49
2019-09-30 $0.20B $0.02B 9.52
2019-06-30 $0.23B $0.03B 8.59
2019-03-31 $0.25B $0.02B 12.89
2018-12-31 $0.26B $0.02B 15.29
2018-09-30 $0.27B $0.02B 15.97
2018-06-30 $0.27B $0.02B 16.33
2018-03-31 $0.28B $0.01B 19.78
2017-12-31 $0.18B $0.01B 13.90
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.868B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.991B 9.65
GSK (GSK) United Kingdom $72.663B 8.73
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.304B 18.93
Biohaven Pharmaceutical Holding (BHVN) United States $10.553B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.041B 0.00
Myovant Sciences (MYOV) United Kingdom $1.698B 0.00
Emergent Biosolutions (EBS) United States $1.490B 8.64
Zymeworks (ZYME) Canada $0.404B 0.00
Enzo Biochem (ENZ) United States $0.131B 0.00
Gelesis Holdings (GLS) United States $0.117B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00